63 Results

People

  1. Drilon
    Drilon
  2. Schram
    Schram
  3. Hyman
    Hyman
  4. Li
    Li
  5. Guo
    Guo
  6. Kris
    Kris
  7. Ladanyi
    Ladanyi
  8. Harding
    Harding
  9. Hechtman
    Hechtman
  10. Benayed
    Benayed

Groups

  1. Department of Medicine (63)
  2. Gynecologic Medicine Service (63)
  3. Solid Tumor Oncology Division (63)
  4. Thoracic Oncology (63)
  5. Early Drug Development Service (50)
  6. GSK Faculty (34)
  7. Gastrointestinal Oncology Service (29)
  8. Human Oncology and Pathogenesis Program (29)
  9. Sloan Kettering Institute Postdocs (26)
  10. Gynecology Disease Management Team (22)
  1. "Department of Medicine"
  2. "Alexander Drilon"
  3. "Gynecologic Medicine Service"
Formats
  1. Journal Article (32)
  2. Meeting Abstract (28)
  3. Review (2)
  4. Research Letter (1)
Groups
  1. Department of Medicine (63)
  2. Gynecologic Medicine Service (63)
  3. Solid Tumor Oncology Division (63)
  4. Thoracic Oncology (63)
  5. Early Drug Development Service (50)
  6. GSK Faculty (34)

More Groups

People
  1. Alexander Drilon (63)
  2. Alison Schram (45)
  3. David Hyman (28)
  4. Marc Ladanyi (18)
  5. Michael Berger (16)
  6. Bob Li (14)

More People

Years
  1. 2024 (1)
  2. 2023 (4)
  3. 2022 (6)
  4. 2021 (13)
  5. 2020 (11)
  6. 2019 (17)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Annals of Oncology (7)
  3. JCO Precision Oncology (7)
  4. Cancer Research (6)
  5. Clinical Cancer Research (5)
  6. Cancer Discovery (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (23)
  2. American Association for Cancer Research (16)
  3. Elsevier Inc. (7)
  4. Oxford University Press (7)
  5. Nature Publishing Group (5)
  6. American Medical Association (1)

More Publishers

Results (63)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quantifying the expanding landscape of clinical actionability for patients with cancer
    Journal Article

    Suehnholz, S. P.; Nissan, M. H.; Zhang, H.; Kundra, R.; Nandakumar, S.; Lu, C.; Carrero, S.; Dhaneshwar, A.; Fernandez, N.; Xu, B. W.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
    Meeting Abstract

    Choudhury, N. J.; Harada, G.; Whiting, K.; Shen, R.; Yang, S. R.; Solit, D. B.; Berger, M. F.; Dinapoli, S.; Abou-Alfa, G. K.; Iyer, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
    Journal Article

    Murciano-Goroff, Y. R.; Schram, A. M.; Rosen, E. Y.; Won, H.; Gong, Y.; Noronha, A. M.; Janjigian, Y. Y.; Stadler, Z. K.; Chang, J. C.; Yang, S. R.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision
    Review

    Lai, G. G. Y.; Guo, R.; Drilon, A.; Tan, D. S. W.
    Cancer Treatment Reviews (2022)

    Fulltext@MSK | Save